期刊文献+

托特罗定PLGA微球的制备及其体外释药的研究

Preparation of tolterodine PLGA micorspheres and its in vitro release properties
原文传递
导出
摘要 目的:考察制备工艺对托特罗定微球的体外性质的影响。方法:采用O/W溶剂挥发法制备托特罗定聚乳酸-羟基乙酸共聚物[poly(lactic-co-glycolic acid),PLGA]微球,采用扫描电镜,差示扫描量热分析,红外光谱对微球进行定性分析,并对微球的粒径、包封率和体外释放率等性质进行了考察。结果:托特罗定微球光滑圆整,粒径均一。PLGA相对分子质量对微球的包封率和体外释放度影响较大。脂肪酸能显著改善微球的包封率,但是对体外释放的影响有限。结论:制备工艺参数的变化对托特罗定PLGA微球体外性质影响显著。 Objective:To investigate the impact of preparation technique on in vitro release properties of tolterodine-loaded microspheres. Methods: Tolterodine poly (lactic-co-glycolic acid) (PLGA) microspheres were prepared with O/W emulsion solvent evaporation method and characterized by SEM,DSC and FT-IR. The particle size,encapsulation efficiency,and in vitro release rate of tolterodine from the microspheres were studied. Results: The microspheres were spherical in shape with a smooth surface. The effects of the molecular weight of PLGA on the encapsulation efficiency and in vitro release rate were significant. The fattic acids significantly improved the drug encapsulation,but showed limited effects on the in vitro release of toherodine from microspheres. Conclusion: The impact of formulation factors on in vitro release properties of tolterodine-loaded microspheres is evident.
出处 《中国新药杂志》 CAS CSCD 北大核心 2012年第23期2821-2825,共5页 Chinese Journal of New Drugs
关键词 托特罗定 微球 PLGA 体外释药 toherodine microspheres PLGA in vitro releasing
  • 相关文献

参考文献5

  • 1WITTE LP, MULDER WM,DE LA ROSETTE JJ,et al. Muscarinie receptor antagonists for overactive bladder treatment:does one fit all[J]. Curr Opin Urol,2009,19( 1 ) :13 - 19.
  • 2OISHI M ,CHIBA K,MALHOTRA B ,et al. Effect of the CYP2D6 * 10 genotype on tolterodine pharmacokinetics[J]. Drug Metab Dispos,2010,38(9) :1456 - 1463.
  • 3ZOLNIK BS,BURGESS DJ. Evaluation of in vivo-in vitro release of dexamethasone from plga microspheres [ J ]. J Control Release, 2008,127(2) :137 - 145.
  • 4SU ZX,SUN FY,SHI YN,et al. Effects of formulation parameters on encapsulation efficiency and release behavior of risperidone poly (D,L-lactide-co-glycolide) microsphere [ J ]. Chem Pharm Bull, 2009,57(11) :1251 -1256.
  • 5杨阳,高永良.制备工艺对盐酸噻吩诺啡微球体外释放度的影响[J].中国新药杂志,2011,20(3):267-269. 被引量:2

二级参考文献6

  • 1李妍妍,高永良,王东援,郑宁,张颖,田文辉.HPLC法测定盐酸噻诺啡片的含量及其溶出度[J].中国新药杂志,2005,14(5):587-590. 被引量:6
  • 2LANGER R. Biomaterials in drug delivery and tissue engineering:onelaboratory's experience [ J ]. Acc Chem Res ,2000,33 (2) :94 - 101.
  • 3FREITAS S, MERKLE HP, GANDER B. Microencapsulation by solvent extraction/evaporation :reviewing the state of the art of microsphere preparation process technology [ J ]. J Control Release, 2005,102(2) :313 -332.
  • 4FREITAS S, MERKLE HP, GANDER B. Microencapsulation by solvent extraction/evaporation :reviewing the state of the art of microsphere preparation process technology [ J ]. J Control Release, 2005,102(2):313 -332.
  • 5YANG YY, CHUNG TS, PING NG NGEE. Morphology, drug distribution, and in vitro release profiles of biodegradable polymeric microspheres containing protein fabricated by double-emulsion solvent extraction/evaporation method [ J ]. Biomaterials, 2001,22 (3) :231 -241.
  • 6SHIVER MS, ANDERSON JM. Biodegradatong and biocompalibility of PLA and PLGA microspheres [ J]. Adv Drug Deliv Rev, 1997,28(1) :5 -24.

共引文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部